SEC Seal
SEC Banner
Search the Next-Generation EDGAR System
Filing Detail
Form 8-K - Current report:
SEC Accession No. 0001193125-24-070838
Filing Date
2024-03-19
Accepted
2024-03-19 08:44:53
Documents
14
Period of Report
2024-03-14
Items
Item 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers
Item 7.01: Regulation FD Disclosure
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K d800974d8k.htm   iXBRL 8-K 28618
2 EX-99.1 d800974dex991.htm EX-99.1 6405
  Complete submission text file 0001193125-24-070838.txt   158624

Data Files

Seq Description Document Type Size
3 XBRL TAXONOMY EXTENSION SCHEMA itci-20240314.xsd EX-101.SCH 2896
4 XBRL TAXONOMY EXTENSION LABEL LINKBASE itci-20240314_lab.xml EX-101.LAB 17236
5 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE itci-20240314_pre.xml EX-101.PRE 10843
17 EXTRACTED XBRL INSTANCE DOCUMENT d800974d8k_htm.xml XML 3481
Mailing Address 430 EAST 29TH STREET NEW YORK NY 10016
Business Address 430 EAST 29TH STREET NEW YORK NY 10016 212-923-3344
Intra-Cellular Therapies, Inc. (Filer) CIK: 0001567514 (see all company filings)

IRS No.: 364742850 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-36274 | Film No.: 24761201
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)